【SOLUTN 0093 交流专区】方案工程

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Dec 2018

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Dec 2018	31 Dec 2017	31 Dec 2018	31 Dec 2017
		$$'000	$$'000	$$'000	$$'000

1	Revenue	4,443	5,436	13,098	24,334
2	Profit/(loss) before tax	-1,035	319	-3,496	9,948
3	Profit/(loss) for the period	-1,129	168	-3,568	8,381
4	Profit/(loss) attributable to ordinary equity holders of the parent	-1,080	62	-3,400	7,978
5	Basic earnings/(loss) per share (Subunit)	-0.35	0.02	-1.11	2.61
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1254		0.1387

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Mar 2019

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Mar 2019	31 Mar 2018	31 Mar 2019	31 Mar 2018
		$$'000	$$'000	$$'000	$$'000

1	Revenue	3,616	2,516	3,616	2,516
2	Profit/(loss) before tax	-549	-1,250	-549	-1,250
3	Profit/(loss) for the period	-549	-1,250	-549	-1,250
4	Profit/(loss) attributable to ordinary equity holders of the parent	-547	-1,098	-547	-1,098
5	Basic earnings/(loss) per share (Subunit)	-0.18	-0.36	-0.18	-0.36
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1240		0.1258

icy97

SOLUTION ENGINEERING HOLDINGS BERHAD

Kindly be advised that the aforesaid Company has changed its name to "SOLUTION GROUP BERHAD​”. As such, the Company's securities will be traded and quoted under the new name with effect from 9.00 a.m., Tuesday, 11 June 2019, as follows:

Old Name	Old Stock Short Name	New Name	New Stock Short Name
SOLUTION ENGINEERING HOLDINGS BERHAD	SOLUTN	SOLUTION GROUP BERHAD	SOLUTN
SOLUTION ENGINEERING HOLDINGS BERHAD – WARRANTS A	SOLUTN-WA	SOLUTION GROUP BERHAD – WARRANTS A	SOLUTN-WA

The Stock Numbers and Stock Short Names remain unchanged.

icy97

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	SOLUTION GROUP BERHAD (FORMERLY KNOWN AS SOLUTION ENGINEERING HOLDINGS BERHAD) ("SGB" OR "THE COMPANY")(I)        PROPOSED LAND ACQUISITION; (II)        PROPOSED MACHINERY ACQUISITION; AND(III)        PROPOSED DIVERSIFICATION(COLLECTIVELY, THE PROPOSALS)
The Board of Directors of SGB wishes to announce that its wholly-owned subsidiary, Solution E&E Technology Sdn Bhd (“Solution E&E”) had on 21 August 2019 (duly signed copies received on 23 August 2019), entered into 2 separate sale and purchase agreements (“SPA(s)”) with Malaysian Bio-Xcell Sdn Bhd (“BXL”) in relation to the following: Proposed acquisition of a portion of a freehold land held under HSD 479585, PTD 171839, Mukim Pulai, Daerah Johor Bahru, Negeri Johor measuring approximately 6.82 acres (“Land”) upon which is erected with a partially completed Verdepalm Plant (as defined hereunder) erected thereon for a cash consideration of RM18.00 million (“Proposed Land Acquisition”); and Proposed acquisition of machinery and equipment located on the Land for a cash consideration of RM7.00 million (“Proposed Machinery Acquisition”) (Collectively, referred as the “Proposed Acquisitions”) Upon completion of the Proposed Acquisitions, the Company intends to make further investment to complete the construction of the bio-manufacturing plant and thereafter venture into the business of the production of lactic acid. In relation thereto and pursuant to Rule 10.13 of the ACE Market Listing Requirement of Bursa Malaysia Securities Berhad (“Bursa Securities”) (“Listing Requirement”), the Company wishes to diversify its existing businesses to include the production of lactic acid in view of the future profits to be derived from the said business (“Proposed Diversification”). Please refer to the attachment for further information. This announcement is dated 23 August 2019.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/6262973

Attachments SGB - Proposals (Final).pdf

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Jun 2019

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Jun 2019	30 Jun 2018	30 Jun 2019	30 Jun 2018
		$$'000	$$'000	$$'000	$$'000

1	Revenue	5,179	3,059	8,797	5,575
2	Profit/(loss) before tax	216	-739	-333	-1,989
3	Profit/(loss) for the period	216	-739	-333	-1,989
4	Profit/(loss) attributable to ordinary equity holders of the parent	129	-768	-418	-1,866
5	Basic earnings/(loss) per share (Subunit)	0.04	-0.25	-0.14	-0.61
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1245		0.1258

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Sep 2019

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Sep 2019	30 Sep 2018	30 Sep 2019	30 Sep 2018
		$$'000	$$'000	$$'000	$$'000

1	Revenue	4,873	3,081	13,670	8,656
2	Profit/(loss) before tax	235	-469	-98	-2,458
3	Profit/(loss) for the period	309	-446	-24	-2,435
4	Profit/(loss) attributable to ordinary equity holders of the parent	262	-450	-156	-2,316
5	Basic earnings/(loss) per share (Subunit)	0.09	-0.15	-0.05	-0.76
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1253		0.1258

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Dec 2019

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Dec 2019	31 Dec 2018	31 Dec 2019	31 Dec 2018
		$$'000	$$'000	$$'000	$$'000

1	Revenue	5,116	4,443	18,784	13,067
2	Profit/(loss) before tax	-624	-1,035	-722	-3,549
3	Profit/(loss) for the period	-794	-1,129	-818	-3,477
4	Profit/(loss) attributable to ordinary equity holders of the parent	-788	-1,080	-944	-3,300
5	Basic earnings/(loss) per share (Subunit)	-0.26	-0.35	-0.31	-1.08
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1228		0.1258

私人重地

哇，15/9一下子被炒这么高？？

jooye

私人重地 发表于 17-9-2020 06:37 PM
哇，15/9一下子被炒这么高？？

想不到会起死回生

私人重地

jooye 发表于 27-9-2020 01:10 AM
想不到会起死回生

目标价RM3有人说！！

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Mar 2020

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Mar 2020	31 Mar 2019	31 Mar 2020	31 Mar 2019
		$$'000	$$'000	$$'000	$$'000

1	Revenue	3,452	3,616	3,452	3,616
2	Profit/(loss) before tax	-369	-549	-369	-549
3	Profit/(loss) for the period	-369	-549	-369	-549
4	Profit/(loss) attributable to ordinary equity holders of the parent	-396	-547	-396	-547
5	Basic earnings/(loss) per share (Subunit)	-0.13	-0.18	-0.13	-0.18
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1213		0.1228

SUMMARY OF KEY FINANCIAL INFORMATION 30 Jun 2020

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Jun 2020	30 Jun 2019	30 Jun 2020	30 Jun 2019
		$$'000	$$'000	$$'000	$$'000

1	Revenue	3,470	5,179	6,921	8,797
2	Profit/(loss) before tax	115	216	-254	-333
3	Profit/(loss) for the period	115	216	-254	-333
4	Profit/(loss) attributable to ordinary equity holders of the parent	64	129	-332	-418
5	Basic earnings/(loss) per share (Subunit)	0.02	0.04	-0.11	-0.14
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1215		0.1228

jooye

私人重地 发表于 27-9-2020 02:31 PM
目标价RM3有人说！！

那么猛，RM3?!
之前0.50卖了，现在留了1000unit在手。

私人重地

jooye 发表于 12-10-2020 01:39 PM
那么猛，RM3?!
之前0.50卖了，现在留了1000unit在手。

我手上还握着决定跟他搏一把！
话说那个investalk的网页是不是关闭？

eucoo

https://youtu.be/qn6hPNtn0n0

私人重地

楼主没更新的财务报告表

Tony-Pua

0093    SOLUTN    SOLUTION GROUP BERHADQuarterly rpt on consolidated results for the financial period ended 30/09/2020

Quarter:		3rd Quarter
Financial Year End:		31/12/2020
Report Status:		Unaudited
Submitted By:
		Current Year Quarter	Preceding Year Corresponding Quarter	Current Year to Date	Preceding Year Corresponding Period
		30/09/2020	30/09/2019	30/09/2020	30/09/2019
		RM '000	RM '000	RM '000	RM '000
1	Revenue	5,288	4,873	12,209	13,670
2	Profit/Loss Before Tax	577	235	322	(98)
3	Profit/(loss) attributable to ordinary equity holders of the parent	416	262	83	(156)
4	Net Profit/Loss For The Period	577	309	322	(24)
5	Basic Earnings/Loss Per Shares (sen)	0.14	0.09	0.03	(0.05)
6	Dividend Per Share (sen)	0.00	0.00	0.00	0.00
				As At End of Current Quarter	As At Preceding Financial Year End
7	Net Assets Per Share (RM)			0.1244	0.1228

icy97

Type	Announcement
Subject	OTHERS
Description	MEMORANDUM OF UNDERSTANDING BETWEEN SOLUTION GROUP BERHAD ("SGB" OR "THE COMPANY") AND CANSINO BIOLOGICS INC.
The Board of Directors of Solution Group Berhad (“Board”) wishes to announce that SGB had on 3 August 2020 entered into a Memorandum of Understanding (“MOU”) with CanSino Biologics Inc. (“CanSinoBIO”, SHSE: 688185, HKEX:06185) in collaboration on the potential COVID-19 vaccine co-developed by CanSinoBIO (“Projects”) and the Beijing Institute of Biotechnology, Academy of Military Medical Sciences (BIB). Please refer to the attachment for further details. This announcement is dated 19 August 2020.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3079035

Attachments SGBCanSIno MOU.pdf

Type	Announcement
Subject	OTHERS
Description	SOLUTION GROUP BERHAD ("SGB" or "THE COMPANY") - INCORPORATION OF A NEW WHOLLY-OWNED SUBSIDIARY
1. INTRODUCTION The Board of Directors of SGB wishes to announce that SGB had incorporated a new wholly-owned subsidiary, Solution Biologics Sdn. Bhd. (“SOLBIO”). 2. INFORMATION OF SOLBIO SOLBIO was incorporated in Malaysia under the Companies Act 2016 on 17 August 2020. The issued share capital is RM1.00 divided into 1 ordinary share of RM1 each. The paid up will be increased to RM1 million within a month. The intended principal activities of SOLBIO are the establishment of a vaccine fill and finish facility, marketing and distribution of any type of biological drugs. 3. EFFECTS OF THE INCORPORATION SGB shall hold 100% of the total number of issued shares of SOLBIO. 4. FINANCIAL EFFECTS The incorporation of SOLBIO is not expected to have any material effects on the earnings or net assets of the Company for the financial year ending 31 December 2020. 5. DIRECTORS’ AND MAJOR SHAREHOLDERS’ AND/OR PERSONS CONNECTED WITH A DIRECTOR OR MAJOR SHARHOLDER’S INTERESTS Other than their respective interests through SGB, none of the Directors and/or major shareholders or persons connected to them has any interests, direct or indirect, in the aforesaid incorporation. 6. STATEMENT BY THE BOARD OF DIRECTORS The Board of Directors is of the opinion that the incorporation is in the best interest of the Company. This announcement is dated 19 August 2020.

icy97

Type	Reply to Query
Reply to Bursa Malaysia's Query Letter - Reference ID	IQL-21082020-00001
Subject	MEMORANDUM OF UNDERSTANDING BETWEEN SOLUTION GROUP BERHAD ("SGB" OR THE "COMPANY") AND CANSINO BIOLOGICS INC. ("CANSINOBIO") ("MOU")
Description	Reply to Query dated 21 August 2020
Query Letter Contents	We refer to your Company’s announcement dated 19 August 2020, in respect of the aforesaid matter. In this connection, kindly furnish Bursa Securities with the following additional information for public release:- 1) The total capital and investment outlay required to be committed by SGB in connection with the MOU / proposed new business of the fill and finish of bulk COVID-19 vaccine supplied by CanSinoBIO and the marketing and distribution of the said vaccine in Malaysia (“New Business”), the source(s) of funding and the breakdown thereof. 2) The relevant regulatory approvals, permits and/or licenses required to be obtained in order for SGB to perform its responsibilities under the New Business. To also state whether the Company has secured any of these regulatory approvals, permits and/or licences, and the relevant dates of application and approval. 3) The business risks in connection with the MOU / New Business. 4) The stage of development and production of COVID-19 vaccine by CanSinoBIO. 5) The Company’s future plans and prospects in connection with the collaboration / New Business.
We refer to the query from Bursa Malaysia Securities Berhad via their letter dated 21 August 2020 (Ref No : IQL-21082020-00001) in relation to the announcement made by the Company on 19 August 2020 in respect of the Memorandum of Understanding (“MOU”) entered into between the Company and CanSino Biologics Inc. (“CanSinoBIO”) and furnish below the additional information as requested:- 1) Based on the preliminary studies conducted by the Group, the investment of setting up the fill and finish facility is estimated at RM6 million to RM8 million. Provision for working capital is also required to support the business. The Group intends to finance the investment through internal funding, bank borrowings and/or other forms of financing such as equity. 2) The Group is still in the preliminary stage of setting up the facility. The facility will need to comply to Bio Safety Level 2 (“BSL2”) requirements and also cGMP manufacturing standard. The Group has incorporated a new subsidiary, Solution Biologics Sdn Bhd, which will apply to register the vaccine and facility with National Pharmaceutical Regulatory Agency (“NPRA”). 3) The Group may be subject to challenges and initial risks arising from the operation, however with its Directors and key management who have prior experience in biomanufacturing activities will mitigate the risk through continuously review of its operations, cost control policies, cautious budgeting and leveraging on the business acumen. The success of commercialising the vaccine is subject to completion of the phase 3 trial and obtaining the regulatory approvals. 4) The COVID-19 vaccine, Ad5-nCoV is jointly developed by CanSinoBIO and Beijing Institute of Biotechnology, Academy of Military Medical Sciences. The phase II clinical trial for Ad5-nCoV has been completed. CanSino is now preparng for the phase III clinical trail. The Company is currently liaising with several countries and plan to drive the international multi-center phase III clinical trial for Ad5-nCoV as soon as possible. On 11 August 2020, CanSinoBIO being granted the patent "a recombinant novel coronavirus vaccine using human replication-deficient adenovirus as a carrier". The patent application was jointly filed by Beijing Institute of Biotechnology, Academy of Military Medical Sciences and CanSinoBIO. 5) The Group plans to setup a fill and finish facility for the vaccine to be supplied by CanSinoBIO, and to market and distribute the vaccine in Malaysia. This is subject to CanSinoBIO successfully commercialising the vaccine and obtained the relevant approvals. The Malaysian market size is estimated at between RM500 million to RM1 billion for various type of vaccines including COVID-19. The Board believes that the supply of vaccines and biologics possesses the potential to contribute positively to future earnings and the financial position of SGB Group due to biologics and vaccines represent one of the fastest growing classes of therapeutic molecules in modern healthcare. The annual global biologics market is expected to be approximately USD 380 billion by 2024, representing a relatively higher growth rate (~8%) compared to conventional pharmaceuticals. Currently, more than 350 biologics are commercially presented in the biopharmaceuticals market. This announcement is dated 24 August 2020.

icy97

Type	Reply to Query
Reply to Bursa Malaysia's Query Letter - Reference ID	IQL-21082020-00001
Subject	MEMORANDUM OF UNDERSTANDING BETWEEN SOLUTION GROUP BERHAD ("SGB" OR THE "COMPANY") AND CANSINO BIOLOGICS INC. ("CANSINOBIO") ("MOU")
Description	Reply to Query
Query Letter Contents	We refer to your Company’s announcement dated 19 August 2020, in respect of the aforesaid matter. In this connection, kindly furnish Bursa Securities with the following additional information for public release:- 1) The total capital and investment outlay required to be committed by SGB in connection with the MOU / proposed new business of the fill and finish of bulk COVID-19 vaccine supplied by CanSinoBIO and the marketing and distribution of the said vaccine in Malaysia (“New Business”), the source(s) of funding and the breakdown thereof. 2) The relevant regulatory approvals, permits and/or licenses required to be obtained in order for SGB to perform its responsibilities under the New Business. To also state whether the Company has secured any of these regulatory approvals, permits and/or licences, and the relevant dates of application and approval. 3) The business risks in connection with the MOU / New Business. 4) The stage of development and production of COVID-19 vaccine by CanSinoBIO. 5) The Company’s future plans and prospects in connection with the collaboration / New Business.
We refer to our announcement dated 19 August 2020 and the query from Bursa Malaysia Securities Berhad (“Bursa Securities”) dated 21 August 2020 in respect of the Memorandum of Understanding (“MOU”) entered into between the Company and CanSino Biologics Inc. (“CanSinoBIO”). Plase refer to the enclosed for the additional information as required by Bursa Securities pursuant to the Company's reply dated 24 August 2020. This announcement is dated 27 August 2020.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3082036

Attachments MOU-Reply to Query 2.pdf

icy97

Type	Announcement
Subject	OTHERS
Description	REGISTRATION, MANUFACTURING AND COMMERCIALISATION AGREEMENT BETWEEN SOLUTION GROUP BERHAD ("SGB" OR "THE COMPANY") AND CANSINO BIOLOGICS INC.
We refer to the Company’s announcements dated 19 August 2020, 24 August 2020, 27 August 2020 and 2 September 2020.  The Board of Directors of Solution Group Berhad (“Board”) wishes to announce that our subsidiary, Solution Biologics Sdn Bhd (“SOLBIO”), had on 23 September 2020 signed a Registration, Manufacturing and Commercialisation Agreement (“the Agreement”) with CanSino Biologics Inc. (“CanSinoBIO”, SHSE: 688185, HKEX:06185). Please refer to the attachment for further details. This announcement is dated 23 September 2020.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3090147

Attachments SGBCanSIno Signing of RMC Agreement (Final).pdf